BOSTON--(BUSINESS WIRE)--Click to Tweet this News
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, announced that Chief Medical Officer, Dr. Tom Wessel, will lead a panel of thought leaders including National Academy of Sciences member Dr. Bruce Bean, Professor of Neurobiology at Harvard Medical School, regarding chemical neuro stimulation as a new therapeutic modality to treat and prevent muscle cramps and spasms, at the Neuro Advance Boston Conference on October 14, 2015, held at Harvard Medical School.
“Chemical neuro stimulation by activating TRPA1 and TRPV1 ion channels using topical application of small molecules is a new way of treating cramps and spasms,” noted Dr. Bean, Flex Pharma Scientific Co-Founder and Scientific Advisory Board Co-Chair. “This novel approach drives Flex Pharma’s efforts to develop products to treat a wide spectrum of individuals who suffer from debilitating cramps and spasms. We hope that we might be able help athletes suffering from exercise associated muscle cramps, the millions of individuals suffering from nightly night leg cramps (NLC), and potentially patients with severe neuromuscular diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).”
About Neuro Advance Boston
Neuro Advance Boston brings together leading neuro experts from industry and academia along with key members of the healthcare investment community to brainstorm about the most pressing issues facing neuro drug development. Interactive panels feature CEOs, CMOs, CSOs, and Heads of Neuro from top biopharmaceutical companies in the neuro space, along with leading academics and healthcare investors discussing everything from gene therapy to advances in psychiatry to novel therapeutic approaches.
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma's proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers.
Flex Pharma was founded by National Academy of Sciences members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.
Individuals can follow the Company on Twitter (@flexpharma) and the Company's website (http://ir.flex-pharma.com/) to see the latest progress of the Company's pre-launch activities for its consumer product to prevent and treat exercise-associated muscle cramps.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our expectations regarding potential drug and consumer product candidates, the design and timing of ongoing and anticipated clinical studies and our drug development progress. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation: the status, timing, costs, results and interpretation of our clinical studies; the uncertainties inherent in conducting clinical studies; results from our ongoing and planned preclinical development; expectations of our ability to make regulatory filings and obtain and maintain regulatory approvals; results of early clinical studies as indicative of the results of future trials; the inherent uncertainties associated with intellectual property; and other factors discussed in greater detail under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2014 and subsequent filings with the Securities and Exchange Commission (SEC). You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
